Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW INDICATIONS

On August 24, 2022, the FDA accelerated the approval of ibrutinib (Imbruvica; Pharmacyclics), a Bruton tyrosine kinase inhibitor, for chronic graft-versus-host disease (GVHD) in pediatric patients aged ≥1 year whose disease did not respond to ≥1 lines of systemic therapy. Concomitantly, the FDA approved a new oral suspension formulation of ibrutinib for use in this patient population.

Ibrutinib was previously approved for adults with chronic GVHD, marginal-zone lymphoma, Waldenström’s macroglobulinemia, chronic or small lymphocytic leukemia, and mantle-cell lymphoma.

The new indication was based on results of the open-label, multicenter, single-arm iMAGINE trial of 47 pediatric patients and young adults aged 1 year to <22 years with moderate or severe chronic GVHD who required additional treatment after ≥1 systemic therapies.

The main end point was overall response rate (ORR) through week 25. The ORR was 60% (95% confidence interval [CI], 44-74). The median duration of response was 5.3 months (95% CI, 2.8-8.8), and the median time from first response to new systemic therapies for chronic GVHD or death was 14.8 months (95% CI, 4.6-not evaluable).

“The new Imbruvica oral suspension formulation helps address challenges children may have with swallowing capsules or tablets,” said Paul A. Carpenter, MD, of Seattle Children’s Hospital, and a study investigator.

The most common (≥20%) adverse events were anemia, musculoskeletal pain, pyrexia, diarrhea, pneumonia, abdominal pain, stomatitis, thrombocytopenia, and headache.

Related Items
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Rylaze Received FDA Approval of a New Dosing Regimen
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © The Lynx Group, LLC. All rights reserved.